GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genflow Biosciences PLC (OTCPK:GENFF) » Definitions » Debt-to-EBITDA

GENFF (Genflow Biosciences) Debt-to-EBITDA : 0.00 (As of Jun. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Genflow Biosciences Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genflow Biosciences's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Genflow Biosciences's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2024 was $0.00 Mil. Genflow Biosciences's annualized EBITDA for the quarter that ended in Jun. 2024 was $-1.33 Mil. Genflow Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 was 0.00.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genflow Biosciences's Debt-to-EBITDA or its related term are showing as below:

GENFF's Debt-to-EBITDA is not ranked *
in the Biotechnology industry.
Industry Median: 1.54
* Ranked among companies with meaningful Debt-to-EBITDA only.

Genflow Biosciences Debt-to-EBITDA Historical Data

The historical data trend for Genflow Biosciences's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genflow Biosciences Debt-to-EBITDA Chart

Genflow Biosciences Annual Data
Trend Dec21 Dec22 Dec23
Debt-to-EBITDA
- - -

Genflow Biosciences Semi-Annual Data
Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24
Debt-to-EBITDA Get a 7-Day Free Trial - - - - -

Competitive Comparison of Genflow Biosciences's Debt-to-EBITDA

For the Biotechnology subindustry, Genflow Biosciences's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genflow Biosciences's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genflow Biosciences's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genflow Biosciences's Debt-to-EBITDA falls into.


;
;

Genflow Biosciences Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genflow Biosciences's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -2.061
=0.00

Genflow Biosciences's annualized Debt-to-EBITDA for the quarter that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0 + 0) / -1.334
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is two times the quarterly (Jun. 2024) EBITDA data.


Genflow Biosciences  (OTCPK:GENFF) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Genflow Biosciences Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genflow Biosciences's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genflow Biosciences Business Description

Traded in Other Exchanges
Address
6 Heddon Street, London, GBR, W1B 4BT
Genflow Biosciences PLC is a preclinical biotechnology company focused on developing innovative biological interventions aimed at tackling the effects of aging, potentially slowing or halting the aging process and reducing the incidence of age-related diseases and thereby increasing life span. The company is also focused on longevity and the development of therapies to counteract the effects of aging and diseases associated with age.